Keywords
Drug monitoring
Pharmacokinetic
Pharmacodynamic
Digitalics
Heart fealure
Categories
How to Cite
Abstract
Cardiac glycosides have been used for congestive heart failure and certain cardiac arrhythmias for more than 200 years. Despite introducing a variety of new classes of drugs for the management of heart failure, specifically angiotensin-converting enzyme (ACE) inhibitors, b-adrenergic antagonists (blockers), and the aldosterone antagonist spironolactone, digoxin continues to have an important role in long-term outpatient management. However, a narrow margin exists between therapeutic and toxic doses of digoxin, resulting in a high incidence of digoxin toxicity in clinical practice.
A wide variety of placebo-controlled clinical trials have unequivocally shown that treatment with digoxin can improve symptoms, quality of life, and exercise tolerance in patients with mild, moderate, or severe heart failure. The clinical relevance of digoxin therapeutic monitoring is also proved but the SDC (Serum Digoxin Concentrations) required for optimal clinical efficacy and acceptable toxicity remains controversial. In the last years, international guidelines recommend 1.2 ng/mL as an acceptable high level.
In this bibliographic synthesis, we aim to collect pertinent information from the MedLine database about an exposure-effect relationship to assess the evidence level scientific of new digoxin therapeutic monitoring.
References
Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004 Jun 22; 109(24):2959–64. https://doi.org/10.1161/01.cir.0000132482.95686.87
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997 Feb; 336(8):525–533. https://doi.org/10.1056/nejm199702203360801
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct; 29(19):2388–2442. https://doi.org/10.1093/eurheartj/ehn309
Winter ME. Basic clinical pharmacokinetics. Philadelphia, United States: LippincottWilliams and Wilkins; 2009.147-72. [Accessed 14 June 2021]. Available From: https://omkaw.info/nshhdlvmt.pdf
Smith TW, Butler VP Jr, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by immunoassay. N Engl J Med. 1969 Nov 27; 281(22): 1212-6. https://doi.org/10.1056/nejm196911272812203
Lietuvos intensyviosios terapijos draugija „Ūminis širdies nepakankamumas intensyviojoje terapijoje“. (Society of intensive therapy of Lithuania: acute heart failure in the intensive therapy.) Kaunas: Informacijos technologijų mokymo centras; 2006. p. 63-74
Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am Heart J. 1997 Jul; 134(1): 3–12. https://doi.org/10.1016/s0002-8703(97)70100-5
Smith, T.W. Digitalis: Mechanisms of action and clinical use. New Engl J Med. 1988 Feb 11; 318(6)358-65. https://doi.org/10.1056/nejm198802113180606
Nyberg L, Andersson KE, Bertlet A. Bioavailability of digoxin from tablets. II. Radioimmunoassay and disposition pharmacokinetics of digoxin after intravenous administration. Acta Pharm Suec. 1974 Nov; 11(5): 459-470.
Aronson JK. Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet. Mar-Apr1980; 5 (2):137-149. https://doi.org/10.2165/00003088-198005020-00002
Koren G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin Pharmacokinet. 1987 Nov; 13(5):334-43. https://doi.org/10.2165/00003088-198713050-00004
Eric JE, Gheorghiade M. Digoxin. Prog Cardiovas Dis. Jan-Feb 2002; 44(4): 251-66. https://doi.org/10.1053/pcad.2002.31591
Walsh FM, Sode J. Significance of non-steady-state serum digoxin concentrations. Am J Clin Pathol. 1975 Mar; 63(3):446-50. https://doi.org/10.1093/ajcp/63.3.446
Houin G, Royer-Morrot M-J, Lacarelle B. Suivi thérapeutique des digitaliques. In Suivi thérapeutique pharmacologique pour l’adaptation posologique des medicaments. Marquet P ; 2004 : Elsevier SAS. 323-30
Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol. 1992 Jun 4; 69:97G–107G; discussion 106G-107G. https://doi.org/10.1016/0002-9149(92)91258-6
Rathore SS , Curtis PJ, Wang Y, Bristow MR, Krumholz HM. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003 Feb 19; 289(7):871-8. https://doi.org/10.1001/jama.289.7.871
Ahmed A, Rich WM, Love Te, Lloyd-Jones DM, Aban IB, Colucci WS, Et al. Digoxin and Reduction in Mortality and Hospitalization in Heart Failure: A Comprehensive Post-Hoc Analysis of the DIG Trial. Eur Heart J. 2006 Jan; 27(2): 178–86. https://doi.org/10.1093/eurheartj/ehi687
Ahmed A. Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations. J Gerontol A Biol Sci Med Sci. 2007 Mar; 62(3): 323–329. https://doi.org/10.1093/gerona/62.3.323
Adams KF Jr, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Gheorghiade TA, Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial; A Retrospective Analysis. J Am Coll Cardiol. 2005 Aug 2; 46(3):497-504. https://doi.org/10.1016/j.jacc.2005.02.091
Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002 Mar 20;39(6):946-53. https://doi.org/10.1016/s0735-1097(02)01708-4
Hauptman PJ, Kelly RA. Digitalis. Circulation 1999 Mar 9; 99(9):1265–70. https://doi.org/10.1161/01.cir.99.9.1265
Ordog GJ, Benaron S, Bhasin V, Wasserberger J, Balasubramanian S. Serum digoxin levels and mortality in 5,100 patients. Ann Emerg Med. 1987 Jan; 16(1):32-39. https://doi.org/10.1016/s0196-0644(87)80281-0
Eisenstein EL, Yusuf S, Bindal V, Bourassa GM, Horney A, Collins JF, et al. What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results from the DIG Trial. J Card Fail. 2006 Jun; 12(5):336-42. https://doi.org/10.1016/j.cardfail.2006.04.002
HR Ochs, DJ. Greenblatt, G Bodem, JS. Harmatz. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J. 1978 Oct;96 (4): 507-11. https://doi.org/10.1016/0002-8703(78)90162-x
Cusack B, Kelly J, O’Malley K, Noel J, Lavan J, Horgan J. Digoxin in the elderly: Pharmacokinetic consequences of old age. Clin Pharmacol Ther. 1979 Jun;25(6):772-776. https://doi.org/10.1002/cpt1979256772
Ewy GA, Kapadia GG, Yao L, Lullin M, Marcus IF. Digoxin metabolism in the elderly. Circulation. 1969 Apr; 39(4):449-53. https://doi.org/10.1161/01.cir.39.4.449
Rowe JW, Andres R, Tobin JD, et al: The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol. 1976 Mar; 31(2):155-163. https://doi.org/10.1093/geronj/31.2.155
Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Goodman and Gilman’s the pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill; 1996. p. 809–38
Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clinica Chim Acta. 2007 Feb; 377(1-2):1–13. https://doi.org/10.1016/j.cca.2006.08.026
Terra SG, Washam JB, Dunham GD, Gattis WA. therapeutic range of digoxin’s efficacy in heart failure: what is the evidence? Pharmacotherapy. 1999 Oct; 19(10):1123-6. https://doi.org/10.1592/phco.19.15.1123.30570
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2016 Amine Benlmouden and Eliane Billaud
